Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00594698 · ClinicalTrials.gov registry record · Phase 2

Familiarization and Safety Study of PB127 Ultrasound Contrast Agent

A Phase 2 study of Coronary Artery Disease, sponsored by Point Biomedical.

Completed
Registry status
Phase 2
Development phase
150
Enrollment target
20
Study locations

NCT00594698: Completed Phase 2 study of Coronary Artery Disease, sponsored by Point Biomedical.

NCT00594698 is a Phase 2 study of Coronary Artery Disease that has completed, run by Point Biomedical. The registered enrollment target is 150 participants, below the 1,286-participant average among 219 other Coronary Artery Disease trials with a reported enrollment target (88% lower). The trial reports 20 study locations across 11 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00594698, a Phase 2 study of Coronary Artery Disease, has completed, sponsored by Point Biomedical.

COMPLETED
Registry status
Phase 2
Development phase
150 participants
Enrollment target
20
Study locations

Study Summary

The purpose of this study is to evaluate preparation and administration of PB127, echocardiographic images obtained during PB127 administration, and evaluate the safety of PB127.

Conditions Studied

Interventions

  • DRUG PB127 for injectable suspension

Study Locations (20)

California

  • Long Beach VA Medical Center Cardiology Division - Long Beach
  • University of California San Diego Division of Cardiology - San Diego
  • San Francisco VA Medical Center NCIRE - San Francisco
  • University of California San Francisco - San Francisco
  • Stanford University Medical Center - Stanford

Arizona

  • Michael Morgan, MD - Phoenix
  • Heartcare, P.C. - Scottsdale
  • Mayo Clinic Scottsdale - Scottsdale

Missouri

  • Cardiovascular Consultants - Kansas City
  • St. Louis University Medical Center - St Louis
  • Washington University School of Medicine - St Louis

Maine

  • Androscoggin Cardiovascular Associates - Auburn
  • Maine Cardiology Associates - South Portland

District of Columbia

  • Washington Hospital Center Cardiovascular Research Institute - Washington D.C.

Illinois

  • University of Chicago Medical Center - Chicago

Indiana

  • Krannert Institute of Cardiology - Indianapolis

Kansas

  • The Center for Cardiovascular Studies Kramer and Crouse Cardiology - Shawnee Mission

Trial Details

FieldValue
Enrollment Target 150 participants
Start Date 2002-02
Est. Completion 2003-09
Phase Phase 2
Point Biomedical

7 total trials

What the finished NCT00594698 record still lists

NCT00594698 is an interventional study that assigns participants to a tested intervention. The registered 150 participants enrollment target is mid-sized for trials with a published cap, below the 1,286-participant average among 219 other Coronary Artery Disease trials with a reported enrollment target (88% lower).

The record links to 1 condition, with Coronary Artery Disease appearing as the primary indexed condition, and to 1 intervention - of which PB127 for injectable suspension is the first listed.

NCT00594698 names 20 study sites across 11 states, led by California, Arizona, Missouri.

Frequently Asked Questions

What is clinical trial NCT00594698 about?

NCT00594698 is a clinical study titled "Familiarization and Safety Study of PB127 Ultrasound Contrast Agent". The purpose of this study is to evaluate preparation and administration of PB127, echocardiographic images obtained during PB127 administration, and evaluate the safety of PB127.

What is the current status of trial NCT00594698?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 150 participants. The study started on 2002-02. Estimated completion is 2003-09.

What conditions does trial NCT00594698 study?

This clinical trial studies the following conditions: Coronary Artery Disease.

What interventions are being tested in trial NCT00594698?

The interventions under investigation include: PB127 for injectable suspension (DRUG).

Who is sponsoring clinical trial NCT00594698?

This trial is sponsored by Point Biomedical, which has 7 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00594698 being conducted?

This trial has 20 study locations across Arizona, California, District of Columbia, Illinois, Indiana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Coronary Artery Disease

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT00594698's enrollment target sits among peer trials

150 130th of 219 higher than 87 of 219 other Coronary Artery Disease trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Coronary Artery Disease trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00412594 · 150 participants · Phase 2

    Cladribine and Rituximab in Treating Patients With Hairy Cell Leukemia

  • NCT01484730 · 150 participants

    A Pilot Study to Evaluate Multi-Spectral and Laser Speckle Imaging and Multiphoton Microscopy During Vascular Occlusion

  • NCT01985919 · 150 participants

    Protocol for Facilitating the Acquisition of Research Bone Marrow and Blood Samples

  • NCT02016248 · 150 participants · NA

    SBRT Boost for Unfavorable Prostate Cancer'

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT00594698, the US trial registry maintained by the National Library of Medicine. NCT00594698 (mid enrollment · wide site footprint · completed) retrieved and formatted by PlainTrial, see methodology.